Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : GUMM - Eliminate the Common Cold -- Ignore unavailable to you. Want to Upgrade?

To: Madeleine Harrison who wrote (601)	5/18/1999 9:27:00 PM
From: caly	Respond to of 5582

Well, the article does say this... "This study demonstrates the feasibility of receptor blockade as prophylaxis of common cold symptoms." <edit> Oops, that's not quite was Zicam does. If I understand this correctly, tremacamra binds to the ICAM-1 receptors themselves thus preventing the virus from binding, whereas Zicam binds to the virus to prevent it from binding to the receptor. Different approach I think.